title: Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlation with survival in a series of 247 patients.
abstract: OBJECTIVE
  In a previous pilot study, HSP60 expression at the transcriptional (mRNA) level was shown to be a negative prognostic factor in ovarian cancer. The aim of this study was to determine HSP60-expression by means of immunohistochemistry and to correlate the results with survival in a large series of ovarian carcinoma patients with a closed follow-up.
  
  
  METHODS
  Slides from routinely processed, paraffin-embedded tumor blocks belonging to 247 patients with epithelial ovarian carcinoma were studied for the overexpression of HSP60 using the Lk2 monoclonal antibody and the strepatvidin-biotin-peroxidase technique. HSP60-expression was correlated with overall survival by means of life-table analysis and the Kaplan-Meier method.
  
  
  RESULTS
  47 tumors (19%) expressed HSP60. Of them, 12/29 (41.4% positivity) were stage I tumors, whereas only 35 out of the remaining 218 tumors in more advanced surgical stage (16.1%) showed HSP60 staining. This difference was statistically significant (Fisher s exact test; p = 0.004). Even when stratifying stage for stage, the difference between groups still remained statistically significant (Chi square test; p = 0.0095). The survival curve analysis showed a significant difference in favor of those tumors expressing HSP60 (median survival 28 vs. 37 months; log-rank test, p = 0.02).
  
  
  CONCLUSIONS
  Immunohistochemical detection of HSP60-expression in human epithelial ovarian carcinoma is significantly more frequent in tumors from patients with initial stages of the disease. Therefore, HSP60-expression determined by this method is associated with a significantly better prognosis.
authors.affiliation: Universidad del Pais Vasco, Facultad de Medicina, Departamento de Especialidades Medico-Quirùrgicas, Bilbao, Spain. gepscfoj@lg.ehu.es
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: E
authors.initials: E
authors.lastname: Jiménez
authors.forename: K
authors.initials: K
authors.lastname: Marenbach
authors.forename: H
authors.initials: H
authors.lastname: Romero
authors.forename: D
authors.initials: D
authors.lastname: Marx
authors.forename: H
authors.initials: H
authors.lastname: Meden
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D018834:Chaperonin 60 / Q000032:analysis*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D015993:Life Tables; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D018834:Chaperonin 60; D009363:Neoplasm Proteins